Protocol Ledger

NCT03797456 · Phase II · COMPLETED

A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

Interventional Phase II clinical trial protocol NCT03797456 sponsored by Beijing InnoCare Pharma Tech Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-04-01 Enrollment: 111 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03797456
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)111 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03797456
Protocol FieldVerified Registry Value
NCT IdentifierNCT03797456
Consolidated Lead SponsorBeijing InnoCare Pharma Tech Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment111 participants (ACTUAL)
Registered Start Date2019-04-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03797456
Hospital Research SiteLocationSite Profile
Anhui Provincial HospitalHefei, ChinaOpen Hospital Dossier ->
Peking University People's HospitalBeijing, ChinaOpen Hospital Dossier ->
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
Sun Yat-sen University Cancer CenterGuangzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI